Introduction {#Sec1}
============

Total hip arthroplasty (THA) is an effective treatment for end-stage hip osteoarthritis (OA) \[[@CR1]\]. By 2030, the demand for primary THA is estimated to increase to 572,000 \[[@CR2]\]. THA is associated with a large amount of intraoperative blood loss and hidden blood loss \[[@CR3]\]. Extensive blood loss results in cardiovascular complications and the need for a blood transfusion \[[@CR4], [@CR5]\]. Blood transfusion carries the risk of hepatitis virus transmission and immunomodulation, increasing economic costs and prolonging the length of hospital stay \[[@CR6]\]. Therefore, there is an urgent need to identify a safe, effective method of reducing blood loss and blood transfusions after THA.

Several alternatives are available for minimizing blood loss after THA. These include topical fibrin sealants, topical or intravenous tranexamic acid (TXA) \[[@CR7], [@CR8]\], aminocaproic acid \[[@CR3], [@CR9]\] or diluted epinephrine (DEP) \[[@CR10]\]. Recently, administration TXA plus DEP has become popular for THA patients \[[@CR11]\]. DEP enhances coagulation by several mechanisms \[[@CR12]\]. Nevertheless, whether TXA plus DEP is superior to TXA alone remains unclear. To further explore these issues and to identify the best haemostatic techniques for THA, we performed a meta-analysis of all the available randomized controlled trials (RCTs) of patients with THA.

Methods {#Sec2}
=======

This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement issued in 2011 \[[@CR13]\]. Ethical approval was not necessary for this study, as only de-identified pooled data from individual studies were analysed.

Search strategies {#Sec3}
-----------------

We searched PubMed, Embase and Cochrane CENTRAL for relevant studies from the time of inception of these databases to July 10, 2018. The following groups of keywords and medical terms were used for the literature search: "tranexamic acid" AND "epinephrine" (OR "total hip arthroplasty" OR "total hip replacement" OR arthroplasty OR "THA" "THR") AND (random\* OR prospective\* OR trial\*). The language was not restricted to English. We also conducted an additional search by screening the references of eligible studies.

Study eligibility {#Sec4}
-----------------

We evaluated each identified RCT against the following predetermined selection criteria:i.Study population: adults with hip OA eligible for primary THA.ii.Interventions: the review focused on topical or intravenous TXA plus topical DEP, which are commonly used in the management of blood loss after THA, as commonly reported in the literature.iii.Comparator: direct comparisons among any of the four core therapeutic interventions (i.e. DEP alone, topical or intravenous TXA alone and a control group).iv.Outcome measures: the primary outcomes for this review were the need for transfusion, total blood loss, blood loss in drainage and the occurrence of deep venous thrombosis (DVT).

Data extraction {#Sec5}
---------------

Two authors independently extracted the general characteristics and outcomes from the included studies. The following data were extracted from each study: first author, publication year, location, age and number of patients in the intervention and control groups, doses of TXA and DEP, outcomes, transfusion threshold and follow-up. The differences in the extracted data were discussed by a panel of all the reviewers. When there were no clear data or missing data from the included studies, we tried to contact the corresponding author to obtain the relevant data.

Quality assessment {#Sec6}
------------------

Two reviewers independently evaluated the risk of bias using the Cochrane risk-of-bias tool. Seven major domains of bias (selection bias (random sequence generation), selection bias (allocation concealment), performance bias, detection bias, attrition bias, reporting bias and other bias) in each trial were reviewed. Disagreements between the reviewers were resolved by discussion.

Statistically analysis {#Sec7}
----------------------

The risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for the need for transfusion and the occurrence of DVT. The weighted mean difference (WMD) and corresponding CIs were calculated for continuous data (total blood loss, blood loss in drainage). Heterogeneity was explored for all the meta-analyses and quantified using *I*^2^ statistics. When *I*^2^ value was \> 50%, this was considered substantial heterogeneity between studies. If there was a large clinical heterogeneity, a random-effects model was applied to pool the outcome data. A *P* value \< 0.05 was considered statistically significant. All statistical analyses were performed using Stata 12.0 (Stata Corp., College Station, TX). Subgroup analysis was further performed according to the following variables: risk of bias (low or unclear/high), IV TXA dose (≥ 2 g or \< 2 g), topical dose (≥ 2 g or \< 2 g) and transfusion protocol (strict or loose). We categorized the TXA dose of 30 mg/kg into the subgroup of ≥ 2 g. Sensitivity analysis was also performed by omitting each of the studies in turn.

Quality of evidence assessment {#Sec8}
------------------------------

We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to assess the quality of evidence. The assessment includes five items: risk of bias, inconsistency, indirectness, imprecision and publication bias. Each outcome was rated as high, moderate, low or very low. Summary tables were constructed using GRADE Pro version 3.6 (GRADE Working Group).

Results {#Sec9}
=======

Search results {#Sec10}
--------------

A flowchart of study search and selection is presented in Fig. [1](#Fig1){ref-type="fig"}. We identified 320 references (PubMed = 185, Embase = 20, Web of Science = 80, Cochrane Library = 35) in our initial literature search. There were no additional records identified through other sources. After removing duplicates using Endnote X7 software, there were 206 studies remaining. Subsequently, 200 studies were excluded according to the inclusion criteria. Finally, 6 trials with 703 patients met our inclusion criteria and were included in the meta-analysis \[[@CR14]--[@CR19]\]. The general characteristics of the included studies can be seen in Table [1](#Tab1){ref-type="table"}. All trials were published after the year 2015. Five studies were performed in China, and one was performed in Denmark. The mean age of the patients ranged from 50.0 to 69 years. Patients' ages ranged from 21 to 65 years, and all were less than 100 years old.Fig. 1Flow diagram of the study selection processTable 1General characteristic of the included studies. 1, need for transfusion; 2, total blood loss; 3, hidden blood loss; 4, intraoperative blood loss; 5, the occurrence of DVT; 6, the occurrence of hematomaAuthorCountryAge (years, I/C)No. of patients (*n*)InterventionsDose of interventionOutcomesTransfusion thresholdFollow-upGao F 2015China58.6 vs 61.753 vs 54Topical TXA + topical DEP vs topical TXATXA (3 g), DEP (0.25 mg, 1:200000)1, 2, 3, 4, 5, 6Hb \< 70 g/l3 monthsJans O 2016Denmark67 vs 6950 vs 50Intravenous TXA + intravenous DEP vs intravenous TXATXA (1 g), DEP (0.05 μg kg^−1^ min^−1^)2,3,Hb \< 80 g/lAt dischargeLiu JL 2018China50.0 vs 50.2 vs 51.865 vs 65 vs 65Intravenous TXA + DEP vs intravenous TXA + topical DEP vs intravenous TXAIV DEP (1 mg), IV TXA (10 mg/kg), topical DEP (0.25 mg, 1:200000)1, 2, 3, 4, 5, 6Hb \< 70 g/l2 weeksWang JW 2017China67 vs 6945 vs 45Topical TXA + topical DEP vs topical TXATXA (3 g), DEP (0.25 mg, 1:200000)1, 2, 3, 4, 5, 6Hb \< 80 g/l2 monthsZhang JK 2017China62.5 vs 63.121 vs 34Topical TXA + topical DEP vs topical TXATXA (3 g), DEP (0.25 mg, 1:200000)1, 2, 3, 4, 5, 6Hb \< 80 g/l6 monthsZhang JZ 2017China59.8 vs 60.3 vs 58.652 vs 52 vs 52Topical 1 g TXA + topical low dose DEP vs topical 1 g TXA + topical high dose DEP vs topical TXATXA (1 g), DEP (0.125 mg, 0.25 mg, 1:200000)1, 2, 3, 4, 5Hb \< 70 g/l3 months

Quality assessment {#Sec11}
------------------

Data regarding the risk of bias summary and risk of bias graphs for each study are presented in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}, respectively. Three studies had a low risk of bias. The other studies were considered to have an unclear risk of bias.Fig. 2Risk of bias summary for the included RCTs. +, low risk of bias; −, high risk of bias; ?, unclear risk of biasFig. 3Risk of bias graph for the included RCTs

Quality of evidence assessment {#Sec12}
------------------------------

The GRADE evidence profiles are presented in Additional file [1](#MOESM1){ref-type="media"}. The GRADE level of evidence was low for total blood loss, hidden blood loss and intraoperative blood loss; it was moderate for the need for transfusion and the occurrence of DVT and haematoma.

Results of the meta-analysis {#Sec13}
----------------------------

### Need for transfusion {#Sec14}

Five studies were available with information regarding transfusion rate. The pooled results demonstrated that TXA plus DEP was associated with a lower transfusion rate than TXA alone (RR = 0.57, 95% CI 0.38--0.86, *P* = 0.006, Fig. [4](#Fig4){ref-type="fig"}). No heterogeneity was detected (*I*^2^ = 0%, *P* = 0.441), and thus, a fixed-effects model was used. The results of the subgroup analysis are shown in Table [2](#Tab2){ref-type="table"}. The findings of a decreased need for transfusion were consistent for different doses of TXA except for the risk of bias and transfusion protocol.Fig. 4Forest plot for the comparison of the need for transfusion between the TXA plus DEP and TXA alone groupsTable 2Subgroup analysis for the need for transfusionSubgroupNo. trialsRR (95% CI)*P* value*I*^2^ (%)Test of interaction, *P*Risk of bias Low40.60 (0.38, 0.95)0.02835.50.047 Unclear/high30.50 (0.21, 1.16)0.1050Dose of TXA Low40.60 (0.38, 0.93)0.01434.10.125 High30.50 (0.16, 0.84)0.0230Transfusion protocol Strict30.43 (0.18, 1.05)0.06400.043 Loose40.63 (0.40, 0.98)0.04114.5

### Total blood loss {#Sec15}

Five studies were available for analysis of total blood loss. TXA plus DEP led to significantly less total blood loss than TXA alone (WMD = − 209.79, 95% CI − 322.58 to − 97.02, *P* = 0.000; *I*^2^ = 86.5%, *P* = 0.000, Fig. [5](#Fig5){ref-type="fig"}). Thus, we used a random-effects model to pool the relevant data.Fig. 5Forest plot for the comparison of total blood loss between the TXA plus DEP and TXA alone groups

### Hidden blood loss {#Sec16}

Five studies were available for analysing hidden blood loss. TXA plus DEP led to significantly less hidden blood loss than TXA alone (WMD = − 297.74, 95% CI − 379.06 to − 216.42, *P* = 0.000; *I*^2^ = 65.8%, *P* = 0.020, Fig. [6](#Fig6){ref-type="fig"}). Thus, we used a random-effects model to pool the relevant data.Fig. 6Forest plot for the comparison of hidden blood loss between the TXA plus DEP and TXA alone groups

### Intraoperative blood loss {#Sec17}

Four studies were available for analysis of intraoperative blood loss. TXA plus DEP led to significantly less hidden blood loss than TXA alone (WMD = − 74.35, 95% CI − 166.90 to 18.19, *P* = 0.115; *I*^2^ = 98.3%, *P* = 0.000, Fig. [7](#Fig7){ref-type="fig"}). Thus, we used a random-effects model to pool the relevant data.Fig. 7Forest plot for the comparison of intraoperative blood loss between the TXA plus DEP and TXA alone groups

The occurrence of DVT and haematoma {#Sec18}
-----------------------------------

Five studies reported the occurrence of DVT. There was no significant difference in the occurrence of DVT between the TXA plus DEP and TXA alone groups (RR = 1.15, 95% CI 0.46--2.85, *P* = 0.767, Fig. [8](#Fig8){ref-type="fig"}). No heterogeneity was detected (*I*^2^ = 0%, *P* = 0.747); thus, a fixed-effects model was used. Four studies reported the occurrence of haematoma. There was no significant difference in the occurrence of DVT between the TXA plus DEP and the TXA alone groups in terms of the occurrence of haematoma (RR = 1.09, 95% CI 0.35--3.38, *P* = 0.884, Fig. [9](#Fig9){ref-type="fig"}). No heterogeneity was detected (*I*^2^ = 0%, *P* = 0.561); thus, a fixed-effects model was sued.Fig. 8Forest plot for the comparison of the occurrence of DVT between the TXA plus DEP and TXA alone groupsFig. 9Forest plot for the comparison of the occurrence of haematoma between the TXA plus DEP and TXA alone groups

Sensitivity analysis, publication bias {#Sec19}
--------------------------------------

We performed a sensitivity analysis for the need for transfusion (Fig. [10](#Fig10){ref-type="fig"}. The results showed that after omitting the included studies, in turn, the overall effects did not change. The funnel plots were visually assessed and revealed no asymmetry (Fig. [11](#Fig11){ref-type="fig"}); no evidence of publication bias was determined by the Egger linear regression test for the need for transfusion (*P* = 0.72, Fig. [12](#Fig12){ref-type="fig"}),Fig. 10Sensitivity analysis for the need for transfusion after omitting each study in turnFig. 11Funnel plot of the need for transfusionFig. 12Egger's test for publication bias for the need for transfusion

Discussion {#Sec20}
==========

In the current meta-analysis, we evaluated the efficacy and safety of TXA plus DEP for patients with THA. On the basis of the pooled estimates, TXA plus DEP was associated with significantly less total blood loss and subsequent need for transfusion than TXA alone. The use of tanezumab was not associated with a significantly increased risk of DVT or haematoma.

This was not the first meta-analysis. Yu et al. \[[@CR20]\] conducted a meta-analysis comparing TXA plus DEP for blood loss after total joint arthroplasty (THA and total knee arthroplasty). Thus, we could not determine whether TXA plus DEP was certain to have a significant influence on controlling blood loss among patients undergoing THA alone. Moreover, Yu et al. \[[@CR20]\] only included two studies that focused on THA. In this meta-analysis, we ultimately included six studies totalling 703 patients, adding the statistical power of at least 535 cases. Our meta-analysis was the latest and the most comprehensive one, and it generally concurs and further reinforces the results of the previous meta-analysis. Finally, we performed a subgroup-analysis and evaluated the quality of evidence using GRADE to help healthcare professionals make clinical decisions.

The current meta-analysis demonstrated that TXA plus DEP has a beneficial effect on total blood loss. TXA plus DEP was associated with less total blood loss by 209.79 ml than TXA alone. Several meta-analyses have found that TXA has a beneficial role in reducing blood loss in THA patients without increasing DVT occurrence \[[@CR21], [@CR22]\]. TXA can be administered by several routes including topical \[[@CR23]\], intravenous \[[@CR24]\] and oral \[[@CR25]\]. Studies have shown that there was no significant difference among these routes in terms of the total blood loss. Concerning DEP, Jans O et al. \[[@CR15]\] strongly suggested that intravenous DEP could be beneficial for reducing blood loss after THA. The administration of low-dose DEP could act as a procoagulant by increasing platelet aggregation, resulting in an instant 20--30% increase in platelet count \[[@CR26]\]. Furthermore, DEP could activate α-adrenergic and β-adrenergic receptors; therefore, DEP could stimulate the release of several coagulation factors \[[@CR27]\].

We measured hidden blood loss between the TXA plus DEP and TXA alone groups. We found that TXA plus DEP significantly reduced hidden blood loss by 297.74 ml compared with TXA alone. In THA patients, significant blood loss can occur after wound closure, and the proportion of this blood loss is called hidden blood loss. Hidden blood loss accounts for as much as 60% of the total perioperative blood loss \[[@CR28]\]. With the administration of DEP, the procoagulant effects could last for 1--2 h; therefore, oozing could be decreased.

Regarding complications, we measured the occurrences of DVT and haematoma formation. We found that there was no significant difference between the occurrences of DVT and haematoma formation. Regarding the administration of TXA, DVT was the major concern. Several meta-analyses have identified that administration with TXA does not increase the occurrence of DVT \[[@CR29]\]. Due to the incidence rate being relatively small, there is a need for studies to further clarify the risk \[[@CR30]\].

There were several limitations in this meta-analysis: (1) the doses of TXA and DEP varied among the included studies, and the optimal doses of TXA and DEP require further exploration; (2) heterogeneity was large in terms of total blood loss and hidden blood loss, and these two outcomes should be interpreted cautiously; (3) the follow-up period varied among the included studies; thus, complications of TXA plus DEP may have been underestimated; and (4) the sample size was relatively small in the included studies; therefore, high-quality large-scale sample RCTs are needed.

Conclusion {#Sec21}
==========

This meta-analysis suggests that TXA plus DEP has benefits in terms of total blood loss, hidden blood loss and the need for transfusion. Furthermore, TXA plus DEP had no influence on the occurrence of DVT or haematoma formation. Given all the shortcomings of this meta-analysis, further research and analysis are required to draw more reliable conclusions.

Additional file
===============

 {#Sec22}

Additional file 1:Grade evidence for the outcomes. (DOCX 14 kb)

CIs

:   Confidence intervals

DEP

:   Diluted epinephrine

DVT

:   Deep venous thrombosis

OA

:   Osteoarthritis

RCTs

:   Randomized controlled trials

RR

:   Risk ratio

THA

:   Total hip arthroplasty

TXA

:   Tranexamic acid

WMD

:   Weighted mean difference
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